Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Fregonese, FedericaAhuja, Shama D
Akkerman, Onno W
Arakaki-Sanchez, Denise
Ayakaka, Irene
Baghaei, Parvaneh
Bang, Didi
Bastos, Mayara
Benedetti, Andrea
Bonnet, Maryline
Cattamanchi, Adithya
Cegielski, Peter
Chien, Jung-Yien
Cox, Helen
Dedicoat, Martin
Erkens, Connie
Escalante, Patricio
Falzon, Dennis
Garcia-Prats, Anthony J
Gegia, Medea
Gillespie, Stephen H
Glynn, Judith R
Goldberg, Stefan
Griffith, David
Jacobson, Karen R
Johnston, James C
Jones-López, Edward C
Khan, Awal
Koh, Won-Jung
Kritski, Afranio
Lan, Zhi Yi
Lee, Jae Ho
Li, Pei Zhi
Maciel, Ethel L
Galliez, Rafael Mello
Merle, Corinne S C
Munang, Melinda
Narendran, Gopalan
Nguyen, Viet Nhung
Nunn, Andrew
Ohkado, Akihiro
Park, Jong Sun
Phillips, Patrick P J
Ponnuraja, Chinnaiyan
Reves, Randall
Romanowski, Kamila
Seung, Kwonjune
Schaaf, H Simon
Skrahina, Alena
Soolingen, Dick van
Tabarsi, Payam
Trajman, Anete
Trieu, Lisa
Banurekha, Velayutham V
Viiklepp, Piret
Wang, Jann-Yuan
Yoshiyama, Takashi
Menzies, Dick
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis.Published in
Lancet Respir Med 2018; 6(4):265-75Publiekssamenvatting
Isoniazid-resistant, rifampicin-susceptible (INH-R) tuberculosis is the most common form of drug resistance, and is associated with failure, relapse, and acquired rifampicin resistance if treated with first-line anti-tuberculosis drugs. The aim of the study was to compare success, mortality, and acquired rifampicin resistance in patients with INH-R pulmonary tuberculosis given different durations of rifampicin, ethambutol, and pyrazinamide (REZ); a fluoroquinolone plus 6 months or more of REZ; and streptomycin plus a core regimen of REZ.PMID
29595509ae974a485f413a2113503eed53cd6c53
10.1016/S2213-2600(18)30078-X
Scopus Count
Collections
Related articles
- Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
- Authors: Grace AG, Mittal A, Jain S, Tripathy JP, Satyanarayana S, Tharyan P, Kirubakaran R
- Issue date: 2019 Dec 12
- [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
- Authors: Wada M
- Issue date: 2001 Jan
- Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
- Authors: Sharma SK, Sharma A, Kadhiravan T, Tharyan P
- Issue date: 2013 Jul 5
- [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
- Authors: Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H
- Issue date: 2003 Oct
- [Short-course chemotherapy of tuberculosis with pyrazinamide].
- Authors: Asai S, Futsuki Y, Tomari S, Araki J
- Issue date: 1998 Dec